Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Not all acute peripheral facial palsy in children recovers completely: A telediagnostic follow-up study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same author

Acute changes in gait biomechanics in children with cerebral palsy due to barefoot vs. footwear condition - An exploratory study.

Clinical biomechanics (Bristol, Avon)·2026

Same author

Serum neurofilament light chain in paediatric patients treated with natalizumab for highly active multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Same author

De novo variants in LDB1 are linked to distinct neurodevelopmental phenotypes determined by variant location and differing pathomechanisms.

American journal of human genetics·2026

Same author

Immune-metabolic trajectories delineate subgroups in paediatric long COVID.

Nature communications·2026

Same author

Hair Loss and Bronze Discoloration of the Skin in Lupus Erythematosus.

Deutsches Arzteblatt international·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Natalizumab use in pediatric multiple sclerosis.

Peter Huppke¹, Wiebke Stark, Claudia Zürcher

¹Department of Pediatrics and Pediatric Neurology, Faculty of Medicine, Georg August University, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany.

Archives of Neurology

|December 10, 2008

Summary

Natalizumab effectively treated pediatric relapsing-remitting multiple sclerosis (RRMS) in a small case series. This therapy showed good tolerability and improved quality of life in young patients unresponsive to other treatments.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jun 14, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

Neurology
Immunology
Pediatric Medicine

Background:

Natalizumab is an approved treatment for adult relapsing-remitting multiple sclerosis (RRMS).
It targets alpha4 integrins, modulating immune cell trafficking.
Its use in pediatric MS populations requires further investigation.

Observation:

A case report examined three pediatric patients with RRMS.
These patients had previously shown poor response or adverse effects to other immunomodulatory therapies.
Natalizumab was administered every four weeks at 3-5 mg/kg body weight.

Findings:

No relapses occurred in the three pediatric patients during treatment periods of 15-24 months.
Significant improvements in quality of life were reported by all patients.
Follow-up MRI revealed no new T2 lesions or gadolinium-enhancing lesions, and no adverse events were observed with weight-adjusted dosing.

Implications:

Natalizumab demonstrates efficacy and tolerability as a second-line therapy for pediatric RRMS.
This suggests a promising treatment option for young patients with refractory MS.
Further research is warranted to confirm these findings in larger pediatric cohorts.